Drug Trial Radar · NCT04064060
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Last checked: Nov 20, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
665
Planned (sponsor's estimate)
Start
Aug 12, 2019
Primary completion
May 12, 2028
Study completion May 12, 2028
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Aug 21, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following participants: * Participants receiving luspatercept on a parent protocol at the time of their transition to the rollover study, who tolerate the protocol-prescribed regimen in the parent trial and, in the opinion of the investigator, may derive clinical benefit from continuing treatment with luspatercept * Participants in the follow-up phase previously treated with luspatercept or placebo in the parent protocol will continue into long-term post-treatment follow-up in the rollover study until the follow-up commitments are met * The study design is divided into the Transition Phase, Treatment Phase and Follow-up Phase. Participants will enter transition phase and depending on their background will enter either the treatment phase or the Long-term Post-treatment Follow-up (LTPTFU) phase * Transition Phase is defined as one Enrollment visit * Treatment Phase: For participants in luspatercept treatment the dose and schedule of luspatercept in this study will be the same as the last dose and schedule in the parent luspatercept study. This does not apply to participants that are in long-term follow-up from the parent protocol * Follow-up Phase includes: \- 42 Day Safety Follow-up Visit * During the Safety Follow up, the participants will be followed for 42 days after the last dose of luspatercept, for the assessment of safety-related parameters and adverse event (AE) reporting \- Long-term Post-treatment Follow-up (LTPTFU) Phase * Participants will be followed for overall survival every 6 months for at least 5 years from first dose of luspatercept in the parent protocol, or 3 years of post-treatment from last dose, whichever occurs later, or until death, withdrawal of consent, study termination, or until a subject is lost to follow-up. Participants will also be monitored for progression to AML or any malignancies/pre-malignancies. New anticancer or disease related therapies should be collected at the same time schedule Participants transitioning from a parent luspatercept study in post-treatment follow-up (safety or LTPTFU) will continue from the same equivalent point in this rollover study. The ACE-536-LTFU-001 rollover study will be terminated, and relevant participants will discontinue from the study when all participants fulfill 5 years on the study, including treatment and follow-up.
Conditions
- Myelodysplastic Syndromes (MDS)
- Beta-thalassemia
- Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
Interventions
LuspaterceptDrug
Luspatercept (ACE-536), an erythroid maturation agent, is a recombinant fusion protein consisting of a modified form of the extracellular domain (ECD) of the human activin receptor type IIB (ActRIIB) linked to the human immunoglobin G 1 (IgG1) Fc domain. ActRIIB receptor and its ligands are members of the transforming growth factor-β (TGF-β) superfamily. Members of the TGF-β superfamily ligands, through their binding to activin receptors, are involved in modulating the differentiation of late-stage erythrocyte precursors (normoblasts) in the bone marrow. Luspatercept for injection is formulated as a sterile, preservative-free, lyophilized cake/powder. Luspatercept for injection is available in 25 mg and 75 mg vials and when reconstituted with water for injection, each consists of 50 mg/mL luspatercept in a 10 mM citrate buffer-based solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events (AEs)Time frame: From enrollment until at least 42 Day Safety Follow-up Phase
- Number of participants progressing to high/very high risk MDS or AML.Time frame: Enrollment to Long-term post-treatment follow-up (Approximately, 5 years)
- Percentage of participants progressing to high/very high risk MDS or AMLTime frame: Enrollment to Long-term post-treatment follow-up (Approximately, 5 years)
- Number of participants developing other malignancies/pre-malignanciesTime frame: Enrollment to Long-term post-treatment follow-up (Approximately, 5 years)
- Percentage of participants developing other malignancies/pre-malignanciesTime frame: Enrollment to Long-term post-treatment follow-up (Approximately, 5 years)
Locations
143 sites in 22 countries. Site status is shown where the registry gives one.
Local Institution - 968
Los Angeles, California · Completed
Local Institution - 971
Oakland, California · Completed
Local Institution - 978
Stanford, California · Completed
Local Institution - 975
Tampa, Florida · Completed
Local Institution - 970
Chicago, Illinois · Completed
Local Institution - 973
Boston, Massachusetts · Completed
Local Institution - 961
Detroit, Michigan · Completed
Local Institution - 969
New York, New York · Completed
Local Institution - 967
Cleveland, Ohio · Completed
Local Institution - 972
Philadelphia, Pennsylvania · Completed
Vanderbilt - Ingram Cancer Center
Nashville, Tennessee · Withdrawn
The University of Texas - MD Anderson Cancer Center
Houston, Texas · Withdrawn
Royal Prince Alfred Hospital
Camperdown, Australia · Recruiting
Local Institution - 100
South Brisbane, Queensland, Australia · Completed
Royal Adelaide Hospital
Adelaide, South Australia, Australia · Recruiting
Local Institution - 102
Clayton, Victoria, Australia · Completed
Local Institution - 182
Brasschaat, Belgium · Completed
Local Institution - 180
Bruges, Belgium · Completed
Local Institution - 183
Ghent, Belgium · Completed
Local Institution - 184
Leuven, Belgium · Completed
Local Institution - 221
Plovdiv, Bulgaria · Completed
Local Institution - 220
Boulevard, Sofia, Bulgaria · Completed
Local Institution - 262
Toronto, Ontario, Canada · Completed
Local Institution - 260
Toronto, Ontario, Canada · Completed
Local Institution - 263
Toronto, Ontario, Canada · Completed
Local Institution - 131
Beijing, Beijing Municipality, China · Withdrawn
Local Institution - 135
Guangzhou, Guangdong, China · Withdrawn
Local Institution - 132
Shanghai, Shanghai Municipality, China · Withdrawn
Local Institution - 134
Chengdu, Sichuan, China · Withdrawn
Local Institution - 130
Tianjin, Tianjin Municipality, China · Withdrawn
Local Institution - 133
Hangzhou, Zhejiang, China · Withdrawn
Local Institution - 305
Angers, France · Completed
Local Institution - 300
Créteil, France · Completed
Local Institution - 310
La Tronche, France · Completed
Local Institution - 306
Lille, France · Completed
Local Institution - 301
Marseille, France · Completed
Local Institution - 302
Paris, France · Completed
Local Institution - 307
Pessac, France · Withdrawn
Local Institution - 304
Pierre-Bénite, France · Completed
Local Institution - 308
Strasbourg, France · Completed
Showing 40 of 143 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.